BURLINGTON, Mass., Jan. 30,
2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA)
today announced that Dipal Doshi,
Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and
a recognized leader in the biotechnology and pharmaceutical
industries, has been elected to its Board of Directors at its
Annual Meeting of Stockholders held earlier today. Mr. Doshi
was nominated for election by the Board, together with nine
returning directors, in December
2024.
"Mr. Doshi is an extraordinary leader who brings significant
experience in the biotechnology and pharmaceutical industries,"
said John Marotta, President and CEO
of Azenta. "His experience in strategy, operational and commercial
growth, and perspective as a current public company CEO make him a
perfect fit for our Board.
"I am excited to be joining Azenta at a critical time in their
evolution," said Dipal Doshi.
"Azenta's strong market leadership position and its commitment to
growth and innovation is clear. I look forward to collaborating
with the Board and the leadership team to help shape the company's
future and make a meaningful impact."
About Dipal Doshi
Mr. Doshi is the CEO of Entrada Therapeutics and a Member of its
Board of Directors. He previously served as President and CEO from
2017 to 2023. Mr. Doshi has led critical functions in biotechnology
and pharmaceutical companies, including roles focused on business
development, corporate strategy, new product planning, commercial
planning and finance. Prior to joining Entrada, Mr. Doshi was the
Chief Business Officer at Amicus Therapeutics, a global
biotechnology company focused on rare diseases. He has also held
senior-level positions at a healthcare private equity fund and
Catalent. Earlier in his career, Mr. Doshi worked in Merrill
Lynch's Investment Banking Group and held several roles at Eli
Lilly and Company.
Mr. Doshi holds an MBA from The Wharton School of the
University of Pennsylvania and a BA
from Rutgers University. Dipal also serves on the Board of
Directors at āshibio, a privately held, clinical-stage
biotechnology company. He is also a Fellow of the Aspen
Institute and serves on the Board of Advisors of Life Science Cares
Boston.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life
sciences solutions worldwide, enabling impactful breakthroughs and
therapies to market faster. Azenta provides a full suite of
reliable cold-chain sample management solutions and multiomics
services across areas such as drug development, clinical research
and advanced cell therapies for the industry's top pharmaceutical,
biotech, academic and healthcare institutions globally. Our global
team delivers and supports these products and services through our
industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude,
Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in Burlington, MA, with operations
in North America, Europe and Asia. For more
information, please visit www.azenta.com.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor
Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/azenta-announces-the-election-of-dipal-doshi-to-its-board-of-directors-302364799.html
SOURCE Azenta
